Avid Bioservices Inc (CDMO)

[biopharm]

Interesting.... found Peter Kolchinsky as one of the Authors next to Hyerun Choe --- and he runs one hedge fund that digs deep into the finest of all small biotech stocks and for a virologist from Harvard to not know about Bavituximab and PS targeting is ... how shall I say it: IMPOSSIBLE. I'd say Peregrine is one of RA Capital top picks at this time and if its not.... maybe they will soon change their mind.

Farzan M, Mirzakov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H. Tyrosine Sulfation of N-terminal CCR5 facilitates HIV-1 Entry. Cell. 1999 Mar;96(5):667-76.

http://www.scripps.edu/florida/research/faculty/choe

---------------------------------------------------------------

I would bet big money that he knows clearly how well PS targeting works and a little history of Mr. Kolchinsky

Harvard Biotech Club

Peter Kolchinsky is a co-founder and General Partner of RA Capital Management, which has been investing in healthcare companies since 2002. He is a member of the National Academies Board on Global Science and Technology, authored an e-book titled “The Entrepreneur’s Guide to a Biotech Startup”, and serves as an advisor to startup companies and non-profits. Peter received his undergraduate degree in Biology from Cornell University and a Ph.D. in Virology from Harvard University, where he conducted research at Dana-Farber Cancer Institute on the entry mechanism of Human Immunodeficiency Virus (HIV).

http://www.thebiotechclub.org/founders.html

.... and Managing Partner (2001-present) at Boston based -RA Capital Management and Board Member NYAS (where Dr. Rolf Brekken is speaking March 25)

http://www.linkedin.com/pub/peter-kolchinsky/33/a45/22

------------------------------------------------------

The Best Hedge Fund You've Never Heard Of

Aug 27, 2013

By hedge fund standards, these days, RA Capital is a small fund. They have about $300 million under management. And they deploy these assets in a very niche strategy. They only buy about 10 stocks a year. And they have a record of seeing some of those stocks run 100%, 500% and even 1,000% in less than a year.

For 2013, RA Capital is up more than 115% year-to-date. They have four stocks on their books that have gone up more than 200% and one stock that has gone up more than 1,000%.

Better still, their performance through the years has proven to be uncorrelated to the broader stock markets. Even in bad stock markets (like 2008, 2011), they still made money!

So how do they do it?

First, they are run by one of the smartest minds in the biotech world, a Harvard Phd in Virology. His name is Peter Kolchinsky. Kolchinksky is one of the foremost experts in biotech investing. This guy is a bona fide genius.

Second, Kolchinsky runs a highly concentrated portfolio of small undiscovered biotech stocks.

http://voices.yahoo.com/the-best-hedge-fund-youve-never-heard-of-12287793.html

---------------------------------------------------


Small undiscovered biotech stock = Peregrine Pharmaceuticals .... not for long though!

imagine......many here owning a stock that the Kolchinsky's of the world spent over a hundred thousand dollars in IVY League education and the most respected field of virology and here some of us are that we only had to read some articles of AF to lead us the way into Peregrine! : )